The efficacy of colistin monotherapy versus combination therapy with other antimicrobials against carbapenem-resistant Acinetobacter baumannii ST2 isolates
暂无分享,去创建一个
Yong Wang | Yongxin Zhao | Jisheng Zhang | Yanjun Fu | Chunjiang Li | Lan Yu | Xiaoli Zhang | Jiaying Li | Xuecai Fan | Chunjiang Li
[1] Yong Wang,et al. Molecular characterization and epidemiology of carbapenem non-susceptible Enterobacteriaceae isolated from the Eastern region of Heilongjiang Province, China , 2018, BMC Infectious Diseases.
[2] L. Leibovici,et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.
[3] I. Barišić,et al. Arrival of carbapenem-hydrolyzing-oxacillinases in Acinetobacter baumannii in Bosnia and Herzegovina. , 2018, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[4] L. Miller,et al. A Multicenter, Randomized, Double-Blind, Phase 2 Study of the Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis , 2018, Antimicrobial Agents and Chemotherapy.
[5] T. Chatsuwan,et al. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. , 2018, Diagnostic microbiology and infectious disease.
[6] D. O’Callaghan,et al. New Delhi Metallo-β-Lactamase-Producing Carbapenem-Resistant Enterobacteriacae Isolated From Bronchial Washings. , 2017, Irish medical journal.
[7] Y. Ye,et al. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[8] O. Cars,et al. Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments , 2017, Infectious diseases.
[9] Wen-juan Wei,et al. Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: colistin and chloramphenicol. , 2017, International journal of antimicrobial agents.
[10] R. Moniri,et al. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii , 2017, Iranian journal of microbiology.
[11] M. Kempf,et al. Wide spread of OXA-23-producing carbapenem-resistant Acinetobacter baumannii belonging to clonal complex II in different hospitals in Lebanon. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[12] Y. Cong,et al. Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model , 2016, PloS one.
[13] S. Baker,et al. In vitro activity of colistin in antimicrobial combination against carbapenem-resistant Acinetobacter baumannii isolated from patients with ventilator-associated pneumonia in Vietnam , 2015, Journal of medical microbiology.
[14] Yuemei Lu,et al. Transition of bla OXA-58-like to bla OXA-23-like in Acinetobacter baumannii Clinical Isolates in Southern China: An 8-Year Study , 2015, PloS one.
[15] J. Lacherade,et al. Community-acquired Acinetobacter baumannii pneumonia. , 2015, Medecine et maladies infectieuses.
[16] P. Nordmann,et al. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology. , 2015, International journal of antimicrobial agents.
[17] C. Nikam,et al. Molecular characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care laboratory in Mumbai , 2014, European Journal of Clinical Microbiology & Infectious Diseases.
[18] E. Giamarellos‐Bourboulis,et al. Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin , 2014, European Journal of Clinical Microbiology & Infectious Diseases.
[19] G. Signoriello,et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] Russell E. Lewis,et al. Synergistic Activity of Colistin plus Rifampin against Colistin-Resistant KPC-Producing Klebsiella pneumoniae , 2013, Antimicrobial Agents and Chemotherapy.
[21] Rui Wang,et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. , 2012, The Journal of antimicrobial chemotherapy.
[22] P. Nordmann,et al. Carbapenem resistance in Enterobacteriaceae: here is the storm! , 2012, Trends in molecular medicine.
[23] K. Kaye,et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] P. Nordmann,et al. Worldwide Dissemination of the blaOXA-23 Carbapenemase Gene of Acinetobacter baumannii1 , 2010, Emerging infectious diseases.
[25] I. Gould,et al. Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. , 2010, The Journal of antimicrobial chemotherapy.
[26] G. French,et al. Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. , 2006, The Journal of antimicrobial chemotherapy.
[27] M. Kaufmann,et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. , 2006, FEMS microbiology letters.
[28] P. Patsalos,et al. The Importance of Drug Interactions in Epilepsy Therapy , 2002, Epilepsia.